2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Chronic Lymphoid Leukemia: new trials by email Literature Review of Chronic Lymphoid Leukemia trials Research Report on Chronic Lymphoid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers rituximab, ABT-263 - CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia | Phase 1 | Completed | AbbVie | 29 | 2009-07-21 | 2025-02-20 |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies ABT-263 - Chronic Lymphoid Leukemia, Lymphoid Malignancies | Phase 1 / Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 81 | 2006-11-01 | 2021-08-02 |
Leukemia, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Hematologic Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Mycosis Fungoides (1) · Sezary Syndrome (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Neoplasms by Site (1)
navitoclax (2) · Rituximab (1)
AbbVie (1) · AbbVie (prior sponsor, Abbott) (1)
United States (2) · Australia (1) · Canada (1)
Mack Mabry, MD (1)